

Electronic supplementary information

Poly-Histidine Grafting Leading to Fishbone-Like Architectures

Vincenzo Razzano,^a Marco Paolino,^a Annalisa Reale,^a Germano Giuliani,^a Roberto Artusi,^b Gianfranco Caselli,^b Michela Visintin,^b Francesco Makovec,^b Alessandro Donati,^a Gianluca Giorgi,^a Francesca Villafiorita-Monteleone,^c Chiara Botta,^c Andrea Cappelli.^{*,a}

^aDipartimento di Biotecnologie, Chimica e Farmacia and European Research Centre for Drug Discovery and Development, Università di Siena, Via A. Moro 2, 53100 Siena, Italy,

^bRottapharm Biotech S.p.A., Via Valosa di Sopra 9, 20900 Monza, Italy,

^cIstituto per lo Studio delle Macromolecole (CNR), Via E. Bassini 15, 20133 Milano, Italy.

E-mail: andrea.cappelli@unisi.it.

Table of contents:

ESI mass spectrum of Ac-His-6-MBHA-1d material	page S2
NMR spectra of compounds 1a-e , 2a-d , 3a-c , 5 , 6a,b , 8	pages S3-S18
Photoluminescence of the polymeric materials obtained by exciting at different wavelengths	page S19




Figure ESI-1. ESI mass spectrum (negative-ion mode) of **Ac-His-6-MBHA-1d** material.




Figure ESI-2. ¹H NMR (500 MHz, CDCl₃) of methyl 2-[acetoxy[6-(prop-2-ynyloxy)naphthalen-2-yl]methyl]acrylate (**1a**).




Figure ESI-3. ¹³C NMR (125 MHz, CDCl₃) of methyl 2-[acetoxy[6-(prop-2-ynyloxy)naphthalen-2-yl]methyl]acrylate (**1a**).




Figure ESI-4. ¹H NMR (500 MHz, CDCl₃) of methyl 2-[acetoxy(6-ethynynaphthalen-2-yl)methyl]acrylate (**1b**).




Figure ESI-5. ¹³C NMR (125 MHz, CDCl₃) of methyl 2-[acetoxy(6-ethynynaphthalen-2-yl)methyl]acrylate (**1b**).




Figure ESI-6. ^1H NMR (400 MHz, CDCl_3) of 2-(methoxycarbonyl)-1-[6-(prop-2-ynyloxy)naphthalen-2-yl]allyl 2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaoctriacontan-38-oate (**1c**).






Figure ESI-7. ^{13}C NMR (125 MHz, CDCl_3) of 2-(methoxycarbonyl)-1-[6-(prop-2-ynyloxy)naphthalen-2-yl]allyl 2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaoctriacontan-38-oate (**1c**).






Figure ESI-10. ^1H NMR (500 MHz, CDCl_3) of methyl 2-[[6-[1-(2,5,8,11,14,17,20,23,26-nonaooctacosan-28-yl)-1*H*-1,2,3-triazol-4-yl]naphthalen-2-yl](acetoxy)methyl]acrylate (**1e**).




Figure ESI-11. ^{13}C NMR (125 MHz, CDCl_3) of methyl 2-[[6-[1-(2,5,8,11,14,17,20,23,26-nonaooctacosan-28-yl)-1*H*-1,2,3-triazol-4-yl]naphthalen-2-yl](acetoxy)methyl]acrylate (**1e**).




Figure ESI-12. ¹H NMR (500 MHz, CDCl₃) of (*E*)-methyl 2-[(1*H*-imidazol-1-yl)methyl]-3-[6-(prop-2-ynyloxy)naphthalen-2-yl]acrylate (**2a**).




Figure ESI-13. ¹³C NMR (125 MHz, CDCl₃) of (*E*)-methyl 2-[(1*H*-imidazol-1-yl)methyl]-3-[6-(prop-2-ynyloxy)naphthalen-2-yl]acrylate (**2a**).




Figure ESI-14. ¹H NMR (500 MHz, CDCl₃) of (*E*)-methyl 2-[(1*H*-imidazol-1-yl)methyl]-3-(6-ethynylnaphthalen-2-yl)acrylate (**2b**).






Figure ESI-15. ¹³C NMR (125 MHz, CDCl₃) of (*E*)-methyl 2-[(1*H*-imidazol-1-yl)methyl]-3-(6-ethynylnaphthalen-2-yl)acrylate (**2b**).






Figure ESI-18. ^1H NMR (500 MHz, CDCl_3) of (*E*)-methyl 2-[(1*H*-imidazol-1-yl)methyl]-3-[6-[1-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]-1*H*-1,2,3-triazol-4-yl]naphthalen-2-yl]acrylate (**2d**).




Figure ESI-19. ^{13}C NMR (125 MHz, CDCl_3) of (*E*)-methyl 2-[(1*H*-imidazol-1-yl)methyl]-3-[6-[1-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]-1*H*-1,2,3-triazol-4-yl]naphthalen-2-yl]acrylate (**2d**).




Figure ESI-20. ^1H NMR (400 MHz, CDCl_3) of 1,3-bis[[(*E*)-2-(methoxycarbonyl)-3-[6-(prop-2-ynyloxy)naphthalen-2-yl]allyl]-1*H*-imidazol-3-ium chloride (**3a**).




Figure ESI-21. ^{13}C NMR (125 MHz, CDCl_3) of 1,3-bis[[(*E*)-2-(methoxycarbonyl)-3-[6-(prop-2-ynyloxy)naphthalen-2-yl]allyl]-1*H*-imidazol-3-ium chloride (**3a**).




Figure ESI-22. ^1H NMR (400 MHz, CDCl_3) of 1,3-bis[[*(E)*-3-(6-ethynynaphthalen-2-yl)-2-(methoxycarbonyl)allyl]-1*H*-imidazol-3-ium chloride (**3b**).




Figure ESI-23. ^{13}C NMR (125 MHz, CDCl_3) of 1,3-bis[[*(E)*-3-(6-ethynynaphthalen-2-yl)-2-(methoxycarbonyl)allyl]-1*H*-imidazol-3-ium chloride (**3b**).




Figure ESI-24. ^1H NMR (500 MHz, CDCl_3) of 2-acetamido-3-[1,3-bis[(*E*)-3-(6-ethynylnaphthalen-2-yl)-2-(methoxycarbonyl)allyl]-1*H*-imidazol-3-ium-4-yl]propanoate (**3c**).




Figure ESI-25. ^{13}C NMR (125 MHz, CDCl_3) of 2-acetamido-3-[1,3-bis[(*E*)-3-(6-ethynylnaphthalen-2-yl)-2-(methoxycarbonyl)allyl]-1*H*-imidazol-3-ium-4-yl]propanoate (**3c**).




Figure ESI-26. ^1H NMR (500 MHz, CDCl_3) of 6-(prop-2-ynyloxy)-2-naphthaldehyde (**5**).




Figure ESI-27. ^{13}C NMR (125 MHz, CDCl_3) of 6-(prop-2-ynyloxy)-2-naphthaldehyde (**5**).




Figure ESI-28. ¹H NMR (400 MHz, CDCl₃) of methyl 2-[hydroxyl[6-(prop-2-ynyloxy)naphthalen-2-yl]methyl]acrylate (**6a**).




Figure ESI-29. ¹³C NMR (125 MHz, CDCl₃) of methyl 2-[hydroxyl[6-(prop-2-ynyloxy)naphthalen-2-yl]methyl]acrylate (**6a**).






Figure ESI-32. ¹H NMR (500 MHz, CDCl₃) of 6-ethynyl-2-naphthaldehyde (8).




Figure ESI-33. ¹³C NMR (125 MHz, CDCl₃) of 6-ethynyl-2-naphthaldehyde (8).




Figure ESI-34. Photoluminescence of polymeric material **Ac-His-6-MBHA-1d** obtained by exciting at different wavelengths.




Figure ESI-35. Photoluminescence of polymeric material **Ac-His-6-MBHA-1e** obtained by exciting at different wavelengths.